IκB Genetic Polymorphisms and Invasive Pneumococcal Disease

I B Genetic Polymorphisms and Invasive Pneumococcal Disease

The Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, United Kingdom; Oxford Centre for Respiratory Medicine, Churchill Hospital Site, Oxford Radcliffe Hospital, Oxford, United Kingdom; Department of Respiratory Medicine, Royal Berkshire Hospital, Reading, United Kingdom; Department of Paediatrics, John Radcliffe Hospital, Oxford, United Kingdom; Centre for Medical Microbi...

Invasive pneumococcal disease.

INTRODUCTION Streptococcus pneumoniae, the pneumococcus, is a Gram-positive diplococcus with more than 90 serotypes determined by the polysaccharide composition of its capsule. It is carried asymptomatically in approximately 50% of people.1 It can cause both non-invasive and invasive disease. Invasive pneumococcal disease (IPD) refers to disease in which the bacterium enters a sterile site such...

Invasive pneumococcal disease and India.

1. Thomas K. Prospective multicentre hospital surveillance of Streptococcus pneumoniae disease in India. Invasive Bacterial Infection Surveillance (IBIS) Group, International Clinical Epidemiology Network (INCLEN). Lancet. 1999;353:1216-21. 2. Shah AS, Nisarga R, Ravi Kumar KL, Hubler R, Herrera G, Kilgore PE. Establishment of population-based surveillance for invasive pneumococcal disease in B...

invasive pneumococcal disease; a serious and preventable infection

Pneumococcal Conjugate Vaccine and Clinically Suspected Invasive Pneumococcal Disease.

OBJECTIVE Ten-valent pneumococcal conjugate vaccine (PCV10) was earlier shown to reduce clinically suspected, non-laboratory-confirmed invasive pneumococcal disease (IPD) in a cluster-randomized trial (the Finnish Invasive Pneumococcal disease trial). PCV10 was introduced into the Finnish national vaccination program in September 2010 using a 3-dose schedule. We evaluated the impact of PCV10 on...